Abstract
The main objective of these studies was to investigate whether the nanoparticle delivery has any immunopotentiation effect at modest doses of a few micro- or nanograms of CpG oligodeoxynucleotide (CpG ODN) and what would be the influence on T cell responses at such low doses. Various doses (5 to 0.05 μg) of a model CpG ODN adjuvant (ܢ) along with 2 Lf tetanus toxoid (TT) were formulated in either nanoparticles using poly(D,L-lactic-coglycolic acid) (PLGA) 50:50 co-polymer, or saline. Strong antigen specific ex vivo T cell proliferation was observed for the Balb / c mice receiving immunogens in nanoparticles. At 5 μg dose of CpG ODN, the T cell stimulation index (SI) was 241 as compared with 74 for the same dose when given in saline. Comparable SI value of 78 was observed at 100-fold lower dose (0.05 μg) using nanoparticles. Similarly, significantly higher (P < 0.01) cytokine secretion was observed for nanoparticles groups. A ten-fold lower dose (0.5 μg instead of 5 μg) of CpG ODN in nanoparticles was adequate to obtain levels of IFN-γ, TNF-α, and IL-2 comparable to those observed following immunisations in saline. The immunopotentiation effect of the particulate delivery on antibody response (total IgG and subtypes) was not so marked. These studies emphasise that antigen delivery in biodegradable nanoparticles can facilitate induction of strong T cell responses, particularly of the Th1 type, at extremely lower doses of CpG ODN. Such reduction in the effective dose would be advantageous for minimising the potential side effects of these novel adjuvants.
Keywords: cpg dna, immunostimulatory cpg motifs, nanospheres, vaccine delivery, plga
Current Drug Delivery
Title: Dose Sparing of CpG Oligodeoxynucleotide Vaccine Adjuvants by Nanoparticle Delivery
Volume: 1 Issue: 4
Author(s): Manish Diwan, Praveen Elamanchili, Min Cao and John Samuel
Affiliation:
Keywords: cpg dna, immunostimulatory cpg motifs, nanospheres, vaccine delivery, plga
Abstract: The main objective of these studies was to investigate whether the nanoparticle delivery has any immunopotentiation effect at modest doses of a few micro- or nanograms of CpG oligodeoxynucleotide (CpG ODN) and what would be the influence on T cell responses at such low doses. Various doses (5 to 0.05 μg) of a model CpG ODN adjuvant (ܢ) along with 2 Lf tetanus toxoid (TT) were formulated in either nanoparticles using poly(D,L-lactic-coglycolic acid) (PLGA) 50:50 co-polymer, or saline. Strong antigen specific ex vivo T cell proliferation was observed for the Balb / c mice receiving immunogens in nanoparticles. At 5 μg dose of CpG ODN, the T cell stimulation index (SI) was 241 as compared with 74 for the same dose when given in saline. Comparable SI value of 78 was observed at 100-fold lower dose (0.05 μg) using nanoparticles. Similarly, significantly higher (P < 0.01) cytokine secretion was observed for nanoparticles groups. A ten-fold lower dose (0.5 μg instead of 5 μg) of CpG ODN in nanoparticles was adequate to obtain levels of IFN-γ, TNF-α, and IL-2 comparable to those observed following immunisations in saline. The immunopotentiation effect of the particulate delivery on antibody response (total IgG and subtypes) was not so marked. These studies emphasise that antigen delivery in biodegradable nanoparticles can facilitate induction of strong T cell responses, particularly of the Th1 type, at extremely lower doses of CpG ODN. Such reduction in the effective dose would be advantageous for minimising the potential side effects of these novel adjuvants.
Export Options
About this article
Cite this article as:
Diwan Manish, Elamanchili Praveen, Cao Min and Samuel John, Dose Sparing of CpG Oligodeoxynucleotide Vaccine Adjuvants by Nanoparticle Delivery, Current Drug Delivery 2004; 1 (4) . https://dx.doi.org/10.2174/1567201043334597
DOI https://dx.doi.org/10.2174/1567201043334597 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmaniasis (VL)
Current Drug Targets Thromboxane A2 Receptor Blockade Prevents Atherosclerotic Process by its Anti-Inflammatory Effect
Vascular Disease Prevention (Discontinued) Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Integrated Transcriptome Analysis of microRNA and mRNA in Mouse Skin Derived Precursors (SKPs) and SKP Derived Fibroblast (SFBs) by RNA-Seq
Current Genomics Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO
Current Drug Targets Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews Oxidative Stress and Post-Stroke Depression: Possible Therapeutic Role of Polyphenols?
Current Medicinal Chemistry The Chemical Structure and Bioactivity of Cycloartane-type Compounds
Current Organic Chemistry Atherosclerosis Potential Drug Targets: Current Scenario and Future Perspectives
Cardiovascular & Hematological Disorders-Drug Targets MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors
Current Cancer Therapy Reviews Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry